Oct 01, 2020 / 04:00PM GMT
Operator
Ladies and gentlemen, welcome to Poxel PXL770 Phase IIa Trial Results Announcement.
I now hand over the call to Mrs. Jonae Barnes, Senior Vice President, Investor Relations, Corporate Communications and Public Relations. Madam, please go ahead.
Jonae R. Barnes - Poxel S.A. - SVP, IR, Corporate Communications & Public Relations
Good afternoon, everyone, and welcome to our conference call today to review the results from the PXL770 Phase IIa trial. I'm Jonae Barnes, Senior Vice President, Investor Relations, Corporate Communications and Public Relations. With me on the call, Thomas Kuhn, CEO; Pascale Fouqueray, Executive Vice President, Clinical Development and Regulatory Affairs; David Moller, Executive Vice President and Chief Scientific Officer; and Julie Dubourg, Medical Director, Clinical Development. They will all be available for Q&A after our call is complete.
Earlier today, we issued a press release for the PXL770 Phase IIa results. For those of you who don't have a copy, you can access it in the Investor Relations section of
Poxel S.A. - Special Call Transcript
Oct 01, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers